Literature DB >> 25963217

Oral tofacitinib for psoriasis: what happens with interrupted treatment?

H Alinia1, S R Feldman2,3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963217     DOI: 10.1111/bjd.13766

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  1 in total

1.  Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Authors:  A Blauvelt; K A Papp; H Sofen; M Augustin; G Yosipovitch; N Katoh; U Mrowietz; M Ohtsuki; Y Poulin; D Shrom; R Burge; K See; L Mallbris; K B Gordon
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-03-31       Impact factor: 6.166

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.